Drug Trial Radar · NCT06323928
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
874
Actual
Start
Apr 1, 2024
Primary completion
Jan 16, 2026
Study completion Mar 16, 2026
Sponsor
- Lead sponsor
- H. Lundbeck A/SIndustry
- Sponsor type
- Industry
- First posted
- Mar 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.
Conditions
- Migraine
Interventions
Lu AG09222Drug
Lu AG09222 will be administered per the arm description.
PlaceboDrug
Placebo matching to Lu AG09222 will be administered per the arm description
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Number of Monthly Migraine Days (MMDs)Time frame: Baseline up to Week 12 (Weeks 1-12)
Locations
120 sites in 14 countries. Site status is shown where the registry gives one.
Accel Research Sites Network - Neurology and Neurodiagnostic of Alabama
Hoover, Alabama
Profound Research - Neurology Center of Southern California
Carlsbad, California
Neurology Center of North Orange County
Fullerton, California
CenExel CNS
Los Alamitos, California
ASCLEPES Research Centers
Sherman Oaks, California
Ki Health Partners LLC DBA New England Institute for Clinical Research
Stamford, Connecticut
K2 Medical Research - Winter Garden
Clermont, Florida
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
K2 Medical Research, LLC - Maitland
Maitland, Florida
Aqualane Clinical Research
Naples, Florida
K2 Medical Research Tampa LLC
Tampa, Florida
Premiere Research Institute Palm Beach
West Palm Beach, Florida
Accellacare and McFarland Clinic
Ames, Iowa
Clinical Research Professionals
Chesterfield, Missouri
Healthcare Research Network
Hazelwood, Missouri
Dent Neurosciences Research Center, Inc.
Amherst, New York
North Suffolk Neurology, PC.
Port Jefferson Station, New York
Accellacare of Cary - Cary Medical Group
Cary, North Carolina
Headache Wellness Center
Greensboro, North Carolina
Raleigh Medical Group
Raleigh, North Carolina
M3 Wake Research, Inc
Raleigh, North Carolina
Accellacare of Rocky Mount
Rocky Mount, North Carolina
Triad Neurological Associates
Winston-Salem, North Carolina
Accellacare of Charleston
Mt. Pleasant, South Carolina
Internal Medicine and Pediatric Associates of Bristol, PC
Bristol, Tennessee
Cedar Health Research, LLC
Dallas, Texas
Mercury Clinical Research
Sugar Land, Texas
MedStar Health - Neurology Clinic at McLean
McLean, Virginia
MC Nevrocentrum
Plovdiv, Bulgaria
University Multiprofile Hospital for Active Treatment Sveti Georgi
Plovdiv, Bulgaria
MC Rusemed-OOD
Rousse, Bulgaria
Diagnostic Consultative Center Convex Ltd
Sofia, Sofiiska, Bulgaria
Dr. Radomir Talab MD, Office of
Hradec Králové, Czechia
Neuros s.r.o
Pilsen, Czechia
Clintrial s. r. o.
Prague, Czechia
DADO MEDICAL s.r.o.
Prague, Czechia
Praglandia s.r.o
Prague, Czechia
Axon Clinical s r.o
Prague, Czechia
Neurologicka ordinace FORBELI sro
Prague, Czechia
Institut neuropsychiatricke pece
Prague, Czechia
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.